Definitive Chemoradiotherapy Versus Trimodality Therapy for Resectable Oesophageal Carcinoma: Meta-analyses and Systematic Review of Literature
- PMID: 30607604
- DOI: 10.1007/s00268-018-04901-z
Definitive Chemoradiotherapy Versus Trimodality Therapy for Resectable Oesophageal Carcinoma: Meta-analyses and Systematic Review of Literature
Abstract
Background: Standard therapy for loco-regionally advanced, resectable oesophageal carcinoma is trimodality therapy (TMT) consisting of neoadjuvant chemoradiotherapy and oesophagectomy. Evidence of survival advantage of TMT over organ-preserving definitive chemoradiotherapy (dCRT) is inconclusive. The aim of this study is to compare survival between TMT and dCRT.
Methods: A systematic review and meta-analyses were conducted. Randomised controlled trials and observational studies on resectable, curatively treated, oesophageal carcinoma patients above 18 years were included. Three online databases were searched for studies comparing TMT with dCRT. Primary outcomes were 1-, 2-, 3- and 5-year overall survival rates. Risk of bias was assessed using the Cochrane risk of bias tools for RCTs and cohort studies. Quality of evidence was evaluated according to Grading of Recommendation Assessment, Development and Evaluation.
Results: Thirty-two studies described in 35 articles were included in this systematic review, and 33 were included in the meta-analyses. Two-, three- and five-year overall survival was significantly lower in dCRT compared to TMT, with relative risks (RRs) of 0.69 (95% CI 0.57-0.83), 0.76 (95% CI 0.63-0.92) and 0.57 (95% CI 0.47-0.71), respectively. When only analysing studies with equal patient groups at baseline, no significant differences for 2-, 3- and 5-year overall survival were found with RRs of 0.83 (95% CI 0.62-1.10), 0.81 (95% CI 0.57-1.14) and 0.63 (95% CI 0.36-1.12).
Conclusion: These meta-analyses do not show clear survival advantage for TMT over dCRT. Only a non-significant trend towards better survival was seen, assuming comparable patient groups at baseline. Non-operative management of oesophageal carcinoma patients might be part of a personalised and tailored treatment approach in future. However, to date hard evidence proving its non-inferiority compared to operative management is lacking.
Comment in
-
Letter to the Editor: Definitive Chemoradiotherapy Versus Trimodality Therapy for Resectable Oesophageal Carcinoma: Meta-analyses and Systematic Review of Literature.World J Surg. 2019 Jul;43(7):1869-1870. doi: 10.1007/s00268-019-04933-z. World J Surg. 2019. PMID: 30706103 No abstract available.
Similar articles
-
The current optimal multimodality treatments for oesophageal squamous-cell carcinoma: A systematic review and meta-analysis.Int J Surg. 2018 Dec;60:88-100. doi: 10.1016/j.ijsu.2018.10.037. Epub 2018 Oct 31. Int J Surg. 2018. PMID: 30389537
-
Survival after neoadjuvant chemoradiotherapy and oesophagectomy versus definitive chemoradiotherapy for patients with oesophageal squamous cell carcinoma.Br J Surg. 2019 Feb;106(3):255-262. doi: 10.1002/bjs.11004. Epub 2018 Nov 5. Br J Surg. 2019. PMID: 30395362
-
Trimodality therapy and definitive chemoradiotherapy for esophageal cancer: a single-center experience and review of the literature.Dis Esophagus. 2015 Oct;28(7):612-8. doi: 10.1111/dote.12242. Epub 2014 May 27. Dis Esophagus. 2015. PMID: 24863560 Review.
-
Outcomes for Esophageal Squamous Cell Carcinoma Treated with Curative Intent in a Western Cohort: Should Multimodal Therapy Be the Gold Standard?World J Surg. 2018 May;42(5):1485-1495. doi: 10.1007/s00268-017-4289-8. World J Surg. 2018. PMID: 29075858
-
The role of definitive chemoradiotherapy versus surgery as initial treatments for potentially resectable esophageal carcinoma.World J Surg Oncol. 2018 Aug 17;16(1):172. doi: 10.1186/s12957-018-1470-y. World J Surg Oncol. 2018. PMID: 30119684 Free PMC article.
Cited by
-
Esophageal cancer practice guidelines 2022 edited by the Japan esophageal society: part 1.Esophagus. 2023 Jul;20(3):343-372. doi: 10.1007/s10388-023-00993-2. Epub 2023 Mar 18. Esophagus. 2023. PMID: 36933136 Free PMC article. No abstract available.
-
Time to surgery in thoracic cancers and prioritization during COVID-19: a systematic review.J Thorac Dis. 2020 Nov;12(11):6640-6654. doi: 10.21037/jtd-20-2400. J Thorac Dis. 2020. PMID: 33282365 Free PMC article.
-
Baseline and interim [18F]FDG-PET/MRI to assess treatment response and survival in patients with M0 esophageal squamous cell carcinoma treated by curative-intent therapy.Cancer Imaging. 2023 Nov 6;23(1):109. doi: 10.1186/s40644-023-00630-2. Cancer Imaging. 2023. PMID: 37932848 Free PMC article. Clinical Trial.
-
Radiomics Signature Facilitates Organ-Saving Strategy in Patients With Esophageal Squamous Cell Cancer Receiving Neoadjuvant Chemoradiotherapy.Front Oncol. 2021 Feb 19;10:615167. doi: 10.3389/fonc.2020.615167. eCollection 2020. Front Oncol. 2021. PMID: 33680935 Free PMC article.
-
Risk Factors for Failure of Direct Oral Feeding Following a Totally Minimally Invasive Esophagectomy.Nutrients. 2021 Oct 15;13(10):3616. doi: 10.3390/nu13103616. Nutrients. 2021. PMID: 34684617 Free PMC article.
References
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical